1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
E-Nitiate Biopharmaceuticals (Hangzhou) Co. Ltd. has 1 pending office action currently active. This action is assigned to 1 distinct examiner, LEE, CHIHYI NMN. The data shows that there are 0 distinct art units associated with this portfolio, which indicates a specific administrative state within the patent office classification process for the pending matter.
LEE, CHIHYI NMN is the busiest examiner for this company, currently overseeing 1 busiest examiner pending office action. Because there is only 1 pending office action in total, this examiner is the sole point of contact for the company's current prosecution efforts. The outcome of the company's active patent work depends entirely on the review conducted by this single individual.
For the applicant, having 1 distinct examiner and 1 pending office action simplifies the prosecution strategy. There is no need to coordinate between different examiners or art units, as the 1 busiest examiner pending action represents the entire active docket. Practitioners should focus on the specific examination history of LEE, CHIHYI NMN to anticipate the next steps for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713607 | NEW CRYSTAL FORM OF COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, CHIHYI NMN | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713607 | NEW CRYSTAL FORM OF COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, CHIHYI NMN | — | §112 | Non-Final OA | — | Pending | May 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialE-Nitiate Biopharmaceuticals (Hangzhou) Co. Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Chihyi Nmn Lee has the most, with 1 of E-Nitiate Biopharmaceuticals (Hangzhou) Co. Ltd.'s pending office actions.
